This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Enrollment
26
Oral Brepocitinib
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Palo Alto, California, United States
Clinical Trial Site
Pasadena, California, United States
Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Safety assessments will consist of monitoring and recording all adverse events (AEs) and SAEs, laboratory evaluation for hematology, blood chemistry, and urinalysis; vital signs; electrocardiograms (ECGs); and physical examinations. The investigator will determine whether the change is clinically meaningful.
Time frame: Screening up to 28 days after the last dose of study drug at 52 weeks
Proportion of participants meeting treatment failure criteria on or after Week 6 up to Week 24
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Trial Site
Lakewood, Colorado, United States
Clinical Trial Site
Waltham, Massachusetts, United States
Clinical Trial Site
St Louis, Missouri, United States
Clinical Trial Site
Palisades Park, New Jersey, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Winston-Salem, North Carolina, United States
Clinical Trial Site
Eugene, Oregon, United States
...and 5 more locations